A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group

The American Journal of Medicine
J McKenneyD Black

Abstract

To assess the lipid-lowering effects and safety of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. We performed a randomized, open-label, parallel-design, active-controlled, study in eight centers in the United States. We enrolled 108 patients with total cholesterol (TC) of > or =200 mg/dL, serum triglycerides (TG) > or =200 and < or =800 mg/dL, and apolipoprotein B (apo B) > or =110 mg/dL. Patients were randomly assigned to receive atorvastatin 10 mg once daily (n=55) or immediate-release niacin 1 g three times daily for 12 weeks (n=53). Patients were stratified based on low-density lipoprotein cholesterol (LDL-C): Patients with LDL-C > or =135 mg/dL were considered to have combined hyperlipidemia and patients with LDL-C <135 mg/dL were considered to have isolated hypertriglyceridemia. The primary outcome measure was percent change from baseline in LDL-C. Other lipid levels were evaluated as secondary parameters. Atorvastatin reduced LDL-C 30% and TC 26% from baseline, and increased high-density lipoprotein cholesterol (HDL-C) 4%. Total TG were reduced 17%. Niacin reduced LDL-C 2%, TC 7%, increased HDL-C 25%, and reduced total TG 29% from baseline. There was a significant diff...Continue Reading

References

Jan 1, 1992·European Journal of Clinical Pharmacology·L SlungaG H Dahlén
Jan 1, 1990·Journal of Cardiovascular Pharmacology·S L Abbate, J D Brunzell
Dec 31, 1991·Clinica Chimica Acta; International Journal of Clinical Chemistry·H G FieselerD Seidel
Jul 1, 1991·Journal of Clinical Pharmacology·J M DroodW H Frishman
Jan 1, 1991·Mayo Clinic Proceedings·J A EtchasonB A Kottke
Jul 11, 1990·JAMA : the Journal of the American Medical Association·Y HenkinJ P Segrest
Aug 1, 1989·Annals of Internal Medicine·G E MullinM C Mitchell
Aug 1, 1986·American Heart Journal·W P Castelli
Feb 1, 1982·European Journal of Clinical Investigation·G Utermann
Mar 2, 1994·JAMA : the Journal of the American Medical Association·J M McKenneyV M Chinchili
Jan 10, 1996·JAMA : the Journal of the American Medical Association·R G Bakker-ArkemaD M Black

❮ Previous
Next ❯

Citations

Jul 27, 2001·The American Journal of Cardiology·J M McKenneyM L Watkins
Jun 17, 2008·Cardiovascular Drugs and Therapy·Fergus McTaggart, Peter Jones
Jun 22, 1999·Clinical Cardiology·D B Hunninghake
Dec 21, 2000·Current Atherosclerosis Reports·S Tavintharan, M L Kashyap
Nov 26, 2010·Current Atherosclerosis Reports·Carlos A DujovneMatthew K Ito
Jul 31, 2013·Cardiovascular Drugs and Therapy·Robert S Rosenson, James A Underberg
Jun 20, 2001·Diabetes, Obesity & Metabolism·J R Burnett, G F Watts
Feb 16, 2016·Current Atherosclerosis Reports·Richard L Dunbar, Harsh Goel
Apr 3, 2008·Mayo Clinic Proceedings·Ronald B Goldberg, Terry A Jacobson
Jun 11, 2003·American Heart Journal·Donald A BerryThomas A Pearson
Nov 15, 2008·Expert Opinion on Therapeutic Targets·Atul Tiwari
Mar 27, 2010·Journal of the American College of Cardiology·Pradeep NatarajanChristopher P Cannon
Jul 12, 2002·The Urologic Clinics of North America·Mark A Moyad
Apr 3, 2004·Journal of Lipid Research·Marleen M J Van GreevenbroekTjerk W A De Bruin
Apr 3, 2010·Therapeutic Advances in Cardiovascular Disease·Carlos M Ferrario
Mar 12, 2015·The Cochrane Database of Systematic Reviews·Stephen P AdamsJames M Wright
Sep 9, 2004·Circulation·Sotirios TsimikasUNKNOWN Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators
Dec 18, 2001·Arteriosclerosis, Thrombosis, and Vascular Biology·D T SteinI Jialal
Apr 23, 2008·Journal of Cardiovascular Pharmacology·Madiha Abdel-MaksoudJohn E Hokanson
Mar 30, 2007·Clinical Pharmacology and Therapeutics·E LaiK Gottesdiener
May 17, 2014·Journal of Separation Science·Homayon Ahmad PanahiMaryam Ejlali
Oct 30, 1998·The Annals of Pharmacotherapy·H S Yee, N T Fong
Jan 26, 2002·The Nurse Practitioner·L T Braun, R S Rosenson
Oct 20, 2005·The Cochrane Database of Systematic Reviews·R P DellavalleL Schilling
Mar 13, 1999·Current Opinion in Lipidology·A Ogunko, M Evans
Feb 16, 2010·Pharmacology & Therapeutics·M John ChapmanPhilippe Giral

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.